Loading…
Tectonic Therapeutic, Inc. is projected to rise to $43.44 by 2027, a +23% move from its current price of $35.27. TECX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $34.00 | $35.30 | $36.65 | +0.09% |
| Jul 14 | $33.50 | $35.33 | $37.26 | +0.18% |
| Jul 15 | $33.14 | $35.36 | $37.74 | +0.27% |
| Jul 16 | $32.83 | $35.40 | $38.16 | +0.36% |
| Jul 17 | $32.57 | $35.43 | $38.53 | +0.45% |
| Jul 18 | $32.34 | $35.46 | $38.88 | +0.54% |
| Jul 19 | $32.13 | $35.49 | $39.20 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.13 | $35.49 | $39.20 | +0.62% |
| Week 2 | $31.03 | $35.71 | $41.11 | +1.25% |
| Week 3 | $30.25 | $35.94 | $42.69 | +1.89% |
| Week 4 | $29.64 | $36.16 | $44.12 | +2.52% |
| Week 5 | $29.13 | $36.39 | $45.45 | +3.16% |
| Week 6 | $28.70 | $36.61 | $46.71 | +3.81% |
| Week 7 | $28.32 | $36.84 | $47.93 | +4.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tectonic Therapeutic, Inc. (TECX) is a biotechnology company focused on discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin.
It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
TECX trades at $35.22 and has a market cap of $664.57M, with a rank of 2814. The current price and market position place it among smaller-cap biotechnology stocks with GPCR-focused therapies.
The price outlook shown in the forecast indicates rising averages over time, starting from $35.22 in 2026 and moving toward higher levels in later years, including a 2030 average of $95.42 and a 2050 average of $839.42. The forecast also outlines a wide spread between min and max prices across years, underscoring substantial upside potential as well as uncertainty.
For 2026, the forecast shows an average of $35.22 with a neutral sentiment; by 2027 the average rises to $42.91 with bullish sentiment, and by 2050 the average is $839.42 with bullish sentiment. Max forecasts reach $1,838.12 in 2050, illustrating the breadth of possible outcomes.
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
The nearest ceiling, 7.5% above — a clean break opens room to run.
A major ceiling 24.0% above — clearing it would confirm fresh momentum.
Key TECX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TECX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.38 | Sell | $35.01 | Buy |
| MA 10 | $34.70 | Buy | $34.40 | Buy |
| MA 20 | $32.44 | Buy | $33.02 | Buy |
| MA 50 | $30.20 | Buy | $30.99 | Buy |
| MA 100 | $29.42 | Buy | $28.97 | Buy |
| MA 200 | $24.26 | Buy | $26.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.96 | Neutral |
| Stoch RSI (14) | 6.15 | Buy |
| CCI (20) | 55.80 | Neutral |
| Williams %R (14) | -46.90 | Info |
| MACD (12,26,9) | 0.24 | Buy |
| ROC (12) | 12.36 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 53.10 | Neutral |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 4.31 | Buy |
| Ultimate (7,14,28) | 54.37 | Neutral |
| Momentum (10) | 3.34 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 35.53 | Sell |
| ADX (14) | 18.98 | Neutral |
| ATR (14) | 1.11 | Info |
The 30-day technical picture is bullish overall. RSI(14) is 60, consistent with positive momentum.
The stock’s near-term trend is supported by a 50-day simple moving average of $29.63 and a 200-day simple moving average of $23.85, suggesting a positive drift relative to longer-term averages.
Near-term support sits at $27.43, while resistance is at $37.93. The 30-day price range spans from $26.91 to $46.10, highlighting a favorable but potentially volatile trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.80 | $35.27 | $52.08 | 0% | Neutral | |
| $33.37 | $43.44 | $60.50 | +23% | Bullish | |
| $43.24 | $58.58 | $85.62 | +66% | Bullish | |
| $57.22 | $80.17 | $121.63 | +127% | Bullish | |
| $65.53 | $94.61 | $148.09 | +168% | Bullish | |
| $78.48 | $116.46 | $187.30 | +230% | Bullish | |
| $83.32 | $126.87 | $209.03 | +260% | Bullish | |
| $83.26 | $129.92 | $218.77 | +268% | Bullish | |
| $90.73 | $144.94 | $248.96 | +311% | Bullish | |
| $110.00 | $179.74 | $314.49 | +410% | Bullish | |
| $159.23 | $288.93 | $545.76 | +719% | Bullish | |
| $377.13 | $828.24 | $1,745.75 | +22.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.80 | $35.27 | $43.30 | +0.00% |
| August 2026 | $31.88 | $38.02 | $46.84 | +7.80% |
| September 2026 | $31.76 | $38.25 | $47.84 | +0.61% |
| October 2026 | $30.64 | $37.21 | $47.12 | -2.73% |
| November 2026 | $31.38 | $38.38 | $49.11 | +3.14% |
| December 2026 | $32.73 | $40.30 | $52.08 | +5.02% |
Click any year to see its month-by-month TECX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TECX price prediction for 2026 points to an average of $35.27 (low $18.80, high $52.08) — a potential gain of 0% on today's $35.27. A consolidation phase looks the most probable path here.
In 2027, TECX is projected to trade between $33.37 and $60.50, averaging $43.44 — a potential gain of +23% from today's $35.27. That is up +23% on the projected 2026 average. Momentum favours further upside here.
Tectonic Therapeutic, Inc.'s 2028 outlook centres on $58.58, within a $43.24 to $85.62 range. That is up +35% on the projected 2027 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, TECX could reach as high as $121.63, with a base case around $80.17 and support toward $57.22 — roughly +127% from $35.27. Momentum favours further upside here.
Expect TECX to range from $65.53 to $148.09 through 2030. The $94.61 average target implies a +168% move from current prices. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The TECX price prediction for 2031 points to an average of $116.46 (low $78.48, high $187.30) — a potential gain of +230% on today's $35.27. Momentum favours further upside here.
In 2032, TECX is projected to trade between $83.32 and $209.03, averaging $126.87 — a potential gain of +260% from today's $35.27. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Tectonic Therapeutic, Inc.'s 2033 outlook centres on $129.92, within a $83.26 to $218.77 range. That is up +2% on the projected 2032 average. That marks a +268% change versus current levels. Momentum favours further upside here.
By 2034, TECX could reach as high as $248.96, with a base case around $144.94 and support toward $90.73 — roughly +311% from $35.27. Buyers look set to stay in control over this stretch.
Expect TECX to range from $110.00 to $314.49 through 2035. The $179.74 average target implies a +410% move from current prices. That is up +24% on the projected 2034 average. Momentum favours further upside here.
The TECX price prediction for 2040 points to an average of $288.93 (low $159.23, high $545.76) — a potential gain of +719% on today's $35.27. Buyers look set to stay in control over this stretch.
In 2050, TECX is projected to trade between $377.13 and $1,745.75, averaging $828.24 — a potential gain of +22.5x from today's $35.27. That is up +187% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TECX today (≈ 28.352708 TECX) could be worth
$23,482.83
+$22,482.83 (+2248%) by 2050 · US Dollar
Based on the average projected TECX price of $828.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TECXwould be worth at today's price.
$1,000 invested in TECX on Jul 10, 2025 (≈ 46.040517 TECX) would be worth
$1,623.85
+$623.85 (+62.4%) today · 1.62× · US Dollar
Based on a TECX entry price of $21.72 vs. today's $35.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.93 | $929.87 | -7.0% |
| 1 month ago | $28.05 | $1,257.4 | +25.7% |
| 3 months ago | $30.72 | $1,148.11 | +14.8% |
| 6 months ago | $19.6 | $1,799.49 | +79.9% |
| 1 year ago | $21.72 | $1,623.85 | +62.4% |
| All time (5.0y) ago | $95.4 | $369.71 | -63.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TECX forecast.
Our base-case forecast reaches $71.00 around 2029.
Implied market cap at $71.00: $1.34B
The multi-year forecast shows a bullish trajectory with varying yearly expectations. The 2026 forecast is neutral, while 2027 onward carries bullish sentiment with rising averages and sizable upside potential.
Key long-range numbers include a 2030 average of $95.42 with a 170.9% ROI, a 2040 average of $289.68 with a 722.5% ROI, and a 2050 average of $839.42 with a 2283.3% ROI. The forecasted max prices expand from $52.77 in 2026 to $1,838.12 in 2050, reflecting wide potential outcomes alongside strong upside.
These estimates imply meaningful appreciation over the forecast horizon, but they also come with substantial uncertainty given the wide min/max ranges and the inherent volatility of biotechnology stocks.
Tap a question to reveal the answer.
2030 forecast: min $64.62, avg $95.42, max $152.75, ROI 170.9%, sentiment BULLISH.
Long-range numbers show bullish sentiment from 2027 onward, with averages rising from $42.91 (2027) to $95.42 (2030), $289.68 (2040), and $839.42 (2050); ROI ranges from 21.9% to 2283.3%.
Yes. The forecast shows 2031 with an average of $118.68 and 2032 with $127.41, while 2030’s average is $95.42. The min/max for 2031 are $77.94/$195.52.
The 30-day range is $26.91 to $46.10.
Current price is $35.22 and market cap is $664.57M.
Tectonic Therapeutic, Inc. Community Discussion
0Share your Tectonic Therapeutic, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.